- Home
- CRSR vs GYRE Comparison
CRSR vs GYRE Comparison
Compare CRSR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSR
- GYRE
- Stock Information
- Founded
- CRSR 1994
- GYRE 2002
- Country
- CRSR United States
- GYRE United States
- Employees
- CRSR N/A
- GYRE N/A
- Industry
- CRSR Computer Manufacturing
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CRSR Technology
- GYRE Health Care
- Exchange
- CRSR Nasdaq
- GYRE Nasdaq
- Market Cap
- CRSR 958.7M
- GYRE 897.1M
- IPO Year
- CRSR 2020
- GYRE N/A
- Fundamental
- Price
- CRSR $9.21
- GYRE $8.13
- Analyst Decision
- CRSR Buy
- GYRE
- Analyst Count
- CRSR 6
- GYRE 0
- Target Price
- CRSR $10.00
- GYRE N/A
- AVG Volume (30 Days)
- CRSR 532.6K
- GYRE 219.2K
- Earning Date
- CRSR 07-31-2025
- GYRE 08-12-2025
- Dividend Yield
- CRSR N/A
- GYRE N/A
- EPS Growth
- CRSR N/A
- GYRE N/A
- EPS
- CRSR N/A
- GYRE 0.02
- Revenue
- CRSR $1,348,872,000.00
- GYRE $100,643,000.00
- Revenue This Year
- CRSR $14.40
- GYRE $21.04
- Revenue Next Year
- CRSR $9.76
- GYRE $89.64
- P/E Ratio
- CRSR N/A
- GYRE $101.65
- Revenue Growth
- CRSR N/A
- GYRE N/A
- 52 Week Low
- CRSR $5.60
- GYRE $6.11
- 52 Week High
- CRSR $13.02
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- CRSR 61.87
- GYRE 48.99
- Support Level
- CRSR $9.28
- GYRE $6.98
- Resistance Level
- CRSR $9.68
- GYRE $7.80
- Average True Range (ATR)
- CRSR 0.33
- GYRE 0.49
- MACD
- CRSR -0.01
- GYRE 0.05
- Stochastic Oscillator
- CRSR 85.02
- GYRE 73.25
About CRSR Corsair Gaming Inc.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.